Krakow, Poland

Centrum Nowoczesnych Terapii Dobry Lekarz

Systemic Lupus Erythematosus

Atopic Dermatitis

Discoid Lupus Erythematosus

Eczema

Dermatitis

Cough

Cutaneous Lupus Erythematosus

Chronic Cough

M5049

MK-7264

Zabedosertib

BAY1834845

MK-7264-030

Gefapixant

Bayer

Merck KGaA (EMD Serono)

Merck Sharp & Dohme (MSD)

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569\_0003 \[NCT05162586\]).

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Centrum Nowoczesnych Terapii Dobry Lekarz | Krakow, Poland

Site insights

Work at this site?

Active trials

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Trial sponsors